三個皮匠報告
政策庫
new
付費
搜索

抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）-行業數據

抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）
公司首次覆蓋報告 制劑營收均突破 20億元；抗神經類制劑營收呈增長趨勢，從 2021年的 8.39億元逐步增長至 2023年的 12.62億元。從毛利率情況來看，目前公司各類制劑保持較高的
其它 下載Excel 下載圖片 原圖定位
圖片屬性
圖片格式：PNG 圖片大?。?31KB 圖片尺寸：2327*778
同報告圖片
 / 35
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第1頁
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
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第2頁
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第3頁
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
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第4頁
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
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第5頁
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
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第6頁
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
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第7頁
fCDlubTku70gfCDkuK3lm70gfCDnvo7lm70gfCDmrKfmtLIgfCDlhbbku5YgfAp8LS0tLS0tfC0tLS0tLXwtLS0tLS18LS0tLS0tfC0tLS0tLXwKfCAyMDIxIHwgMTAgICB8IDUgICAgfCA1ICAgIHwgNCAgICB8CnwgMjAyMiB8IDEwICAgfCA1ICAgIHwgNSAgICB8IDkgICAgfAp8IDIwMjMgfCAxMyAgIHwgNSAgICB8IDUgICAgfCAyMCAgIHwKCui1hOaWmeadpea6kO+8muWFrOWPuOWFrOWRiuOAgeW8gOa6kOivgeWIuOeglOeptuaJgA==
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第8頁
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第9頁
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
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第10頁
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第11頁
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第12頁
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
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第13頁
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
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第14頁
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第15頁
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第16頁
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第17頁
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第18頁
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第19頁
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第20頁
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第21頁
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第22頁
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第23頁
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第24頁
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第25頁
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第26頁
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第27頁
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第28頁
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
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第29頁
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第30頁
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
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第31頁
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
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第32頁
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第33頁
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第34頁
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第35頁
抗高血壓類制劑的營收規模較大，各類制劑毛利率維持較高水平（單位：億元）_第36頁
所屬報告： 華海藥業-公司首次覆蓋報告：慢病領域龍頭企業迎來業績收獲期-240819（27頁）.pdf
打包全文圖表

相關數據

最新數據
聯系我們
  • 0731-84720580
  • sgpjbg002
  • 工作日 9:30 - 18:00
關于我們
侵權處理
關于我們

三個皮匠報告專業的行業報告下載站，每日更新，歡迎大家關注！

copyright@2008-2013 長沙景略智創信息技術有限公司版權所有
網站備案/許可證號：湘B2-20190120

客服
商務合作
小程序
服務號
折疊
午夜网日韩中文字幕,日韩Av中文字幕久久,亚洲中文字幕在线一区二区,最新中文字幕在线视频网站